KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bionano Genomics (BNGO) Other Non Operating Income (2018 - 2025)

Historic Other Non Operating Income for Bionano Genomics (BNGO) over the last 8 years, with Q3 2025 value amounting to -$219000.0.

  • Bionano Genomics' Other Non Operating Income rose 6857.96% to -$219000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.9 million, marking a year-over-year increase of 8686.52%. This contributed to the annual value of -$10.1 million for FY2024, which is 5071.47% up from last year.
  • According to the latest figures from Q3 2025, Bionano Genomics' Other Non Operating Income is -$219000.0, which was up 6857.96% from $676000.0 recorded in Q2 2025.
  • In the past 5 years, Bionano Genomics' Other Non Operating Income ranged from a high of $5.1 million in Q1 2025 and a low of -$20.2 million during Q4 2023
  • Its 5-year average for Other Non Operating Income is -$1.4 million, with a median of -$45000.0 in 2023.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first tumbled by 5030750.0% in 2023, then soared by 47325.5% in 2025.
  • Over the past 5 years, Bionano Genomics' Other Non Operating Income (Quarter) stood at -$24000.0 in 2021, then plummeted by 66.67% to -$40000.0 in 2022, then crashed by 50307.5% to -$20.2 million in 2023, then skyrocketed by 58.3% to -$8.4 million in 2024, then skyrocketed by 97.4% to -$219000.0 in 2025.
  • Its Other Non Operating Income was -$219000.0 in Q3 2025, compared to $676000.0 in Q2 2025 and $5.1 million in Q1 2025.